Epidemiology and Microbial Genomics, DTU Food, Technical University of Denmark, Kongens Lyngby, Denmark.
Infect Immun. 2012 Sep;80(9):3179-88. doi: 10.1128/IAI.00473-12. Epub 2012 Jul 2.
Escherichia coli is the most important etiological agent of urinary tract infections (UTIs). Unlike uropathogenic E. coli, which causes symptomatic infections, asymptomatic bacteriuria (ABU) E. coli strains typically lack essential virulence factors and colonize the bladder in the absence of symptoms. While ABU E. coli can persist in the bladder for long periods of time, little is known about the genetic determinants required for its growth and fitness in urine. To identify such genes, we have employed a transposon mutagenesis approach using the prototypic ABU E. coli strain 83972 and the clinical ABU E. coli strain VR89. Six genes involved in the biosynthesis of various amino acids and nucleobases were identified (carB, argE, argC, purA, metE, and ilvC), and site-specific mutants were subsequently constructed in E. coli 83972 and E. coli VR89 for each of these genes. In all cases, these mutants exhibited reduced growth rates and final cell densities in human urine. The growth defects could be complemented in trans as well as by supplementation with the appropriate amino acid or nucleobase. When assessed in vivo in a mouse model, E. coli 83972carAB and 83972argC showed a significantly reduced competitive advantage in the bladder and/or kidney during coinoculation experiments with the parent strain, whereas 83972metE and 83972ilvC did not. Taken together, our data have identified several biosynthesis pathways as new important fitness factors associated with the growth of ABU E. coli in human urine.
大肠埃希菌是尿路感染(UTI)最重要的病原微生物。不同于引起症状性感染的尿路致病性大肠埃希菌,无症状菌尿(ABU)大肠埃希菌株通常缺乏必需的毒力因子,在没有症状的情况下定植于膀胱。虽然 ABU 大肠埃希菌可以在膀胱中长时间存在,但对于其在尿液中生长和适应所需的遗传决定因素知之甚少。为了鉴定这些基因,我们使用转座子突变方法,以原型 ABU 大肠埃希菌株 83972 和临床 ABU 大肠埃希菌株 VR89 为研究对象。鉴定出 6 个参与各种氨基酸和核苷碱基生物合成的基因(carB、argE、argC、purA、metE 和 ilvC),并随后在 E. coli 83972 和 E. coli VR89 中构建了这些基因的定点突变体。在所有情况下,这些突变体在人尿中表现出生长速度和最终细胞密度降低。这些生长缺陷可以通过转座子互补以及添加适当的氨基酸或核苷碱基来弥补。在小鼠模型中进行体内评估时,E. coli 83972carAB 和 83972argC 在与亲本菌株共接种实验中,其在膀胱和/或肾脏中的竞争优势明显降低,而 83972metE 和 83972ilvC 则没有。总之,我们的数据确定了几种生物合成途径作为与 ABU 大肠埃希菌在人尿中生长相关的新的重要适应因子。